loading...| Preferred Name |
adalimumab |
|
| Synonyms |
D2E7 |
|
| Definitions |
A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65216" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65216" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000791684 |
|
| altLabel |
D2E7 Humira immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer LU200134 |
|
| CAS Registry |
331731-18-1 |
|
| cui |
C4048611 C3467755 C1122087 C1171255 |
|
| DATE FIRST PUBLISHED |
2017-12-19 |
|
| Date last modified |
2017-12-19 |
|
| definition |
A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65216" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65216" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C65216 |
|
| notation |
CDR0000791684 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
adalimumab |
|
| tui |
T116 T129 T121 |